The influence of mianserin on TNF-IL-6 and IL-10 serum levels in rats under chronic mild stress

Pharmacological Reports

Volumn 66, Issue 1, 2014, Pages 22-27

  Manikowska, Katarzyna ^a   Mikołajczyk, Monika ^a   Mikołajczak, Przemysław L ^a,b   Bobkiewicz Kozłowska, Teresa ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b INSTITUTE OF NATURAL FIBRES AND MEDICINAL PLANTS   (Poland)

Author keywords

Antidepressants; Depression; Mianserin Cytokines

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MIANSERIN; TUMOR NECROSIS FACTOR ALPHA; ANTIDEPRESSANT AGENT;

ANHEDONIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC MILD STRESS; CHRONIC STRESS; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; MALE; MOLECULAR DYNAMICS; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; RAT; TREATMENT DURATION; ANIMAL; BLOOD; CHRONIC DISEASE; IMMUNOLOGY; MENTAL STRESS; WISTAR RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CHRONIC DISEASE; INTERLEUKIN-10; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MALE; MIANSERIN; RATS; RATS, WISTAR; STRESS, PSYCHOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84899624754     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/j.pharep.2013.06.003     Document Type: Article

References (42)

1. Basterzi AD, Aydemir C, Kisa C, Aksaray S, Tuzer V, Yazici K, et al. IL-6 levels decrease with SSRI treatment in patients with major depression. Hum Psy-chopharmacol Clin Exp 2005;20:473-6 (Pubitemid 41489458)
2. Brustolim D, Ribeiro-dos-Santos R, Kast RE, Altschuler EL, Soares MBP. A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferongamma in mice. Int Immunopharmacol 2006;6:903-7
3. Casarotto PC, Andreatini R. Repeated paroxetine treatment reverses anhedonia induced in rats by chronic mild stress or dexamethasone. Eur Neuropsycho-pharmacol 2007;17:735-42 (Pubitemid 47432838)
4. Castanon N, Leonard BE, Neveu P, Yirmiya R. Effects of antidepressants on cytokine production and actions. Brain Behav Immun 2002;16:569-74 (Pubitemid 35333736)
5. Castanon N, Medina Ch, Mormede C, Dantzer R. Chronic administration of tianeptine balances lipopolysaccharide-induced expression of cytokines in the spleen and hypothalamus of rats. Psychoneuroendocrinology 2004;29:778-90 (Pubitemid 38521240)
6. Clow A. Cytokines and depression. Int Rev Neurobiol 2002;52:255-72
7. Connor TJ, Brewer Ch, Kelly JP, Harkin A. Acute stress suppresses pro-inflam-matory cytokines TNF-a and IL-1h independent of a catecholamine-driven increase in IL-10 production. J Neuroimmunol 2005;159:119-28 (Pubitemid 40126184)
8. Connor TJ, Harkin A, Kelly JP, Leonard E. Olfactory bulbectomy provokes a supperession of interleukin-1b and tumor necrosis factor-a production in response to an in vivo challenge with lipopolysaccharide: effect of chronic desipramine treatment. Neuroimmunomodulation 2000;7:27-35 (Pubitemid 30012576)
9. Connor TJ, Leonard E. Depression, stress, and immunological activation: the role of cytokines in depressive disorders. Life Sci 1998;62:583-606 (Pubitemid 28045567)
10. Connor TJ, Song C, Leonard E, Merali Z, Anisman H. An assessment of the effects of central interlukin-1b,-2,-6, and tumor necrosis factor-a administration on some behavioral, neurochemical, endocrine, and immune parameters in the rat. Neuroscience 1998;84:923-33 (Pubitemid 28137905)
11. Dantzer R, O'Connor JC, Lawson MA, Kelley KW. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 2011;36:426-36
12. De La Garza IIR. Endotoxin-or pro-inflammatory cytokine-induced sickness behavior as an animal model of depression: focus on anhedonia. Neurosci Biobehav Rev 2005;29:761-70
13. Diamond M, Kelly JP, Connor TJ. Antidepressants suppress production of the Th1 cytokine interferon-g, independent of monoamine transporter blockade. Eur Neuropsychopharmacol 2006;16:481-90 (Pubitemid 44311000)
14. Elenkov IJ, Iezzoni DG, Daly A, Harris AG, Chrousos GP. Cytokine dysregula-tion, inflammation and well-being. Neuroimmunomodulation 2005;12: 255-69
15. Eller T, Vasar V, Shlik J, Maron E. Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog Neuropsycho-pharmacol Biol Psychiatry 2008;32:445-50 (Pubitemid 351178962)
16. Ethika Tyagi E, Agrawal R, Nath Ch, Shukla R. Influence of LPS-induced neuroinflammation on acetylcholinesterase activity in rat brain. J Neuroim-munol 2008;205:51-6
17. Henry Ch J, Huang Y, Wynne AM, Godbout JP. Peripheral lipopolysaccharide (LPS) challenge promotes microglial hyperactivity in aged mice that is associated with exaggerated induction of both pro-inflammatory IL-1b and anti-inflammatory IL-10 cytokines. Brain Behav Immun 2009;23:309-17
18. Hernández ME, Mendieta D, Martínez-Fong D, Lorá F, Moreno J, Estrada I, et al. Variations in circulating cytokine levels during 52 week course of treatment with SSRI for major depressive disorder. Eur Neuropsychopharmacol 2008;18:917-24
19. Jayatissa MN, Bisgaard Ch, Tingstro A, Papp M, Wiborg O. Hippocampal cytogenesis correlates to escitalopram-mediated recovery in a chronic mild stress rat model of depression. Neuropsychopharmacology 2006;31:2395-404 (Pubitemid 44607057)
20. Kaster MP, Gadotti VM, Calixto JB, Santos ARS, Rodrigues ALS. Depressive-like behavior induced by tumor necrosis factor-a in mice. Neuropharmacology 2012;62:419-26
21. Kubera M, Symbirtsev A, Basta-Kaim A, Borycz J, Roman A, Papp M, et al. Effect of chronic treatment with imipramine on interleukin 1 and interleukin 2 production by splenocytes obtained from rats subjected to a chronic mild stress model of depression. Pol J Pharmacol 1996;48:503-6 (Pubitemid 26426010)
22. Kubera M, Lin AH, Kenis G, Bosmans E, van Bockstaele D, Maes M. Anti-inflammatory effects of antidepressants through suppression of the interfer-on-gamma/interleukin-10 production ratio. J Clin Psychopharmacol 2001;21: 199-206 (Pubitemid 32221058)
23. Kubera M, Maes M, Holan V, Basta-Kaim A, Roman A, Shani J. Prolonged desipramine treatment increases the production of interleukin-10, an antiin-flammatory cytokine, in C57BL/6 mice subjected to chronic mild stress model of depression. J Affect Disord 2001;63:171-8. (Pubitemid 32200511)
24. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharma-cology 2000;22:370-9 (Pubitemid 30105765)
25. Leo R, Di Lorenzo G, Tesauro M, Razzini C, Forleo GB, Chiricolo G, et al. Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy. J Clin Psychia-try 2006;67:1760-6 (Pubitemid 44955158)
26. Leonard BE. The immune system, depression and the action of antidepres-sants. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:767-80 (Pubitemid 32374966)
27. Leonard BE, Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012;36:764-85
28. Maes M, Kenis G, Kubera M, De Baets M, Steinbusch H, Bosmans E. The negative immunoregulatory effects of fluoxetine in relation to the cAMP-dependent PKA pathway. Int Immunopharmacol 2005;5:609-18 (Pubitemid 40439180)
29. Maes M, Scharpé S, Meltzer HY, Bosmans E, Suy E, Calabrese J, et al. Relation-ships between interleukin-6 activity, acute phase proteins and function of hypothalamic-pituitary-adrenal axis in severe depression. Psychiatry Res 1993;49:11-27 (Pubitemid 23329244)
30. Maes M. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:664-75
31. McEwen BS. The neurobiology of stress: from serendipity to clinical relevance. Brain Res 2000;886:172-89
32. Nishida A, Hisaoka K, Zensho H, Uchitomi Y, Morinobu S, Yamawaki S. Antidepressant drugs and cytokines in mood disorders. Int Immunopharmacol 2002;2:1619-26 (Pubitemid 35284601)
33. O'Brien SM, Scully P, Fitzgerald P, Scott LV, Dinan TG. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatry Res 2007;41:326-31 (Pubitemid 44854992)
34. Pollmacher T, Haack M, Schuld A, Reichenberg A, Yirmiya R (Pubitemid 35333732)
35. Rygula R, Abumaia N, Flugge G, Fuchs E, Ruther E, Havemann-Reinecke U. Anhedonia and motivational deficit in rats: impact of chronic social stress. Behav Brain Res 2005;162:127-34 (Pubitemid 40731540)
36. Schiepers OJG, Wichers MC, Maes M. Cytokines in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:201-17
37. Shen Y, Connor TJ, Nolan Y, Kelly JP, Leonard BE. Differential effect of chronic antidepressant treatments on lipopolysaccharide-induced depressive-like behavioural symptoms in the rat. Life Sci 1999;65:1773-86 (Pubitemid 29481260)
38. Suz ewska A, Rybakowski JK, Laciak M, Mackiewicz A, Sobieska M, Wiktor-owicz K. Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann NY Acad Sci 1995;762:474-6
39. Sun M, Alkon DL. Open space swimming test to index antidepressant activity. J Neurosci Methods 2003;126:35-40 (Pubitemid 36683055)
40. Sutcigil L, Oktenli C, Musabak U, Bozkurt A, Cansever A, Uzun O, et al. Pro-and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy. Clin Dev Immunol 2007;76396:1-6
41. Willner P. Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 2005;52:90-110 (Pubitemid 41160326)
42. Xia Z, DePierre JW, Nassberger L. Tricyclic antidepressant inhibit IL-6, IL-1b, TNFa and release in human blood monocytes and IL-2 and interferon-g in T cells. Immunopharmacology 199634:27-37. (Pubitemid 26284175)